Search Results - "Edan G"

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors: Comi G Filippi M Barkhof F et al.

Source: Lancet. 5/19/2001, Vol. 357 Issue 9268, p1576-1582. 7p.

Register-based incidence of multiple sclerosis in Brittany (north-western France), 2000-2001.

Authors: Yaouanq, J. Tron, I. Kerbrat, A. et al.

Source: Acta Neurologica Scandinavica. May2015, Vol. 131 Issue 5, p321-328. 8p.

Subjects: Disease incidence, Multiple sclerosis, Symptoms, Medical records, Follow-up studies (Medicine)

Geographic Terms: Brittany (France)

DISCRIMEN SALARIAL: ¿Y CÓMO ME ENTERO?

Authors: RODRÍGUEZ, EDAN G. RIVERA¹

Source: Revista Jurídica (08862516). 2012, Vol. 81 Issue 3, p1007-1026. 20p.

Gallium-67 Imaging in Muscular Sarcoidosis.

Authors: Edan, G. Bourguet, P. Delaval, Ph. et al.

Source: Journal of Nuclear Medicine. Jul1984, Vol. 25 Issue 7, p776-778. 3p. 2 Black and White Photographs.

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

Authors: Edan G Comi G Le Page E et al.

Source: Journal of Neurology, Neurosurgery & Psychiatry. Dec2011, Vol. 82 Issue 12, p1344-1350. 7p.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Authors: Fernández, O. Delvecchio, M. Edan, G. et al.

Source: European Journal of Neurology. May2018, Vol. 25 Issue 5, p1-1. 8p. 3 Charts, 3 Graphs.

Subjects: Multiple sclerosis, Neurologists, Conception, Gadolinium, Natalizumab

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Authors: Fernández, O. Delvecchio, M. Edan, G. et al.

Source: European Journal of Neurology. Mar2017, Vol. 24 Issue 3, p516-522. 7p.

Subjects: Multiple sclerosis treatment, Multiple sclerosis diagnosis, Neurologists, Demyelination, Myelin sheath diseases, Virus diseases

Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

Authors: Bonenfant, J. Bajeux, E. Deburghgraeve, V. et al.

Source: European Journal of Neurology. Feb2017, Vol. 24 Issue 2, p237-244. 8p.

Subjects: Multiple sclerosis treatment, Immunological adjuvants, Magnetic resonance imaging of the brain, Immunoregulation, Follow-up studies (Medicine), Evidence-based medicine, Therapeutics

Ten-year prognosis in multiple sclerosis: a better outcome in relapsing−remitting patients but not in primary progressive patients.

Authors: Kerbrat, A. Hamonic, S. Leray, E. et al.

Source: European Journal of Neurology. Mar2015, Vol. 22 Issue 3, p507-507. 8p.

Subjects: Multiple sclerosis, Disease relapse, Disease progression, Medical practice, Physicians, Prognosis

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

Authors: Edan, G. Kappos, L. Montalbán, X. et al.

Source: Journal of Neurology, Neurosurgery & Psychiatry. Nov2014, Vol. 85 Issue 11, p1183-1189. 9p. 2 Charts, 3 Graphs.

A short and validated multiple sclerosis-specific health-related quality of life measurement for routine medical practice.

Authors: Devy, R. Lehert, P. Varlan, E. et al.

Source: European Journal of Neurology. Jun2013, Vol. 20 Issue 6, p935-941. 7p. 5 Charts.

Subjects: Quality of life measurement, Multiple sclerosis treatment, Physician practice acquisitions, Rasch models, Iterative methods (Mathematics)

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

Authors: Kappos L Freedman MS Polman CH et al.

Source: Lancet. 8/4/2007, Vol. 370 Issue 9585, p389-397. 9p.

A Web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis.

Authors: Galea, I. Lederer, C. Neuhaus, A. et al.

Source: European Journal of Neurology. Jul2013, Vol. 20 Issue 7, p1107-1109. 3p. 2 Graphs.

Subjects: Multiple sclerosis, Disease progression, Neurologists, Prognosis, Field research, Health counseling, Patients

Immunosuppressive therapy in multiple sclerosis.

Authors: Edan, G.

Source: Neurological Sciences. May2005 Supplement 1, Vol. 26, ps18-s18. 1p.

Subjects: Immunosuppressive agents, Multiple sclerosis, Virus diseases, Immunosuppression, Immunoregulation, Neurodegeneration

A new approach to evaluation of mutiple sclerosis by isokinetic device.

Authors: Rochcongar P Robineau S Nicolas B et al.

Source: Isokinetics & Exercise Science. 2003, Vol. 11 Issue 1, p81-82.

URL: 9360991

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

Authors: Lefort, M. Sharmin, S. Andersen, J. B. et al.

Source: BMC Medical Research Methodology. 5/30/2022, Vol. 22 Issue 1, p1-14. 14p.

Benefit 11: Long-term follow-up study of patients with clinically isolated syndrome treated with interferon beta-1b.

Authors: Kappos, L. Edan, G. Freedman, M. et al.

Source: Journal of the Neurological Sciences. Oct2013, Vol. 333, pe383-e383. 1p.

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.

Authors: Le Page, E. Leray, E. Edan, G.

Source: Multiple Sclerosis Journal. Jul2011, Vol. 17 Issue 7, p867-875. 9p. 3 Charts, 2 Graphs.

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.

Authors: Ghalie, RG Mauch, E Edan, G et al.

Source: Multiple Sclerosis (13524585). Oct2002, Vol. 8 Issue 5, p441-445. 5p.

HLA-DRB1^*15 allele influences the later course of relapsing remitting multiple sclerosis.

Authors: Cournu-Rebeix, I. Génin, E. Leray, E. et al.

Source: Genes & Immunity. Sep2008, Vol. 9 Issue 6, p570-574. 5p. 4 Charts, 2 Graphs.